These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 29758944)
21. GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future. Maqbool M; Hoda N Curr Pharm Des; 2017 Nov; 23(29):4332-4350. PubMed ID: 28714403 [TBL] [Abstract][Full Text] [Related]
22. Is glycogen synthase kinase-3 a central modulator in mood regulation? Li X; Jope RS Neuropsychopharmacology; 2010 Oct; 35(11):2143-54. PubMed ID: 20668436 [TBL] [Abstract][Full Text] [Related]
23. Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging. Duda P; Wiśniewski J; Wójtowicz T; Wójcicka O; Jaśkiewicz M; Drulis-Fajdasz D; Rakus D; McCubrey JA; Gizak A Expert Opin Ther Targets; 2018 Oct; 22(10):833-848. PubMed ID: 30244615 [TBL] [Abstract][Full Text] [Related]
24. Disease-modified glycogen synthase kinase-3β intervention by melatonin arrests the pathology and memory deficits in an Alzheimer's animal model. Peng CX; Hu J; Liu D; Hong XP; Wu YY; Zhu LQ; Wang JZ Neurobiol Aging; 2013 Jun; 34(6):1555-63. PubMed ID: 23402899 [TBL] [Abstract][Full Text] [Related]
25. Divergent roles of GSK3 and CDK5 in APP processing. Ryder J; Su Y; Liu F; Li B; Zhou Y; Ni B Biochem Biophys Res Commun; 2003 Dec; 312(4):922-9. PubMed ID: 14651959 [TBL] [Abstract][Full Text] [Related]
26. When Good Kinases Go Rogue: GSK3, p38 MAPK and CDKs as Therapeutic Targets for Alzheimer's and Huntington's Disease. D'Mello SR Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072862 [TBL] [Abstract][Full Text] [Related]
27. Advances in tetrahydropyrido[1,2-a]isoindolone (valmerins) series: Potent glycogen synthase kinase 3 and cyclin dependent kinase 5 inhibitors. Boulahjar R; Ouach A; Bourg S; Bonnet P; Lozach O; Meijer L; Guguen-Guillouzo C; Le Guevel R; Lazar S; Akssira M; Troin Y; Guillaumet G; Routier S Eur J Med Chem; 2015 Aug; 101():274-87. PubMed ID: 26142492 [TBL] [Abstract][Full Text] [Related]
28. Kororamides, Convolutamines, and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer's Disease: A Computational Study. Llorach-Pares L; Nonell-Canals A; Avila C; Sanchez-Martinez M Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30332805 [TBL] [Abstract][Full Text] [Related]
29. Maintained activity of glycogen synthase kinase-3beta despite of its phosphorylation at serine-9 in okadaic acid-induced neurodegenerative model. Lim YW; Yoon SY; Choi JE; Kim SM; Lee HS; Choe H; Lee SC; Kim DH Biochem Biophys Res Commun; 2010 Apr; 395(2):207-12. PubMed ID: 20362550 [TBL] [Abstract][Full Text] [Related]
30. Glycogen synthase kinase 3 alteration in Alzheimer disease is related to neurofibrillary tangle formation. Baum L; Hansen L; Masliah E; Saitoh T Mol Chem Neuropathol; 1996; 29(2-3):253-61. PubMed ID: 8971700 [TBL] [Abstract][Full Text] [Related]
32. The new indirubin derivative inhibitors of glycogen synthase kinase-3, 6-BIDECO and 6-BIMYEO, prevent tau phosphorylation and apoptosis induced by the inhibition of protein phosphatase-2A by okadaic acid in cultured neurons. Martin L; Magnaudeix A; Wilson CM; Yardin C; Terro F J Neurosci Res; 2011 Nov; 89(11):1802-11. PubMed ID: 21826701 [TBL] [Abstract][Full Text] [Related]
33. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. Munoz L; Ralay Ranaivo H; Roy SM; Hu W; Craft JM; McNamara LK; Chico LW; Van Eldik LJ; Watterson DM J Neuroinflammation; 2007 Sep; 4():21. PubMed ID: 17784957 [TBL] [Abstract][Full Text] [Related]
34. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors. Avila J; Wandosell F; Hernández F Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491 [TBL] [Abstract][Full Text] [Related]
35. Identification of sequence variants and analysis of the role of the glycogen synthase kinase 3 beta gene and promoter in late onset Alzheimer's disease. Russ C; Lovestone S; Powell JF Mol Psychiatry; 2001 May; 6(3):320-4. PubMed ID: 11326302 [TBL] [Abstract][Full Text] [Related]
36. Newly developed glycogen synthase kinase-3 (GSK-3) inhibitors protect neuronal cells death in amyloid-beta induced cell model and in a transgenic mouse model of Alzheimer's disease. Noh MY; Chun K; Kang BY; Kim H; Park JS; Lee HC; Kim YH; Ku S; Kim SH Biochem Biophys Res Commun; 2013 May; 435(2):274-81. PubMed ID: 23632329 [TBL] [Abstract][Full Text] [Related]
37. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α. Lo Monte F; Kramer T; Gu J; Anumala UR; Marinelli L; La Pietra V; Novellino E; Franco B; Demedts D; Van Leuven F; Fuertes A; Dominguez JM; Plotkin B; Eldar-Finkelman H; Schmidt B J Med Chem; 2012 May; 55(9):4407-24. PubMed ID: 22533818 [TBL] [Abstract][Full Text] [Related]
38. GSK3: a possible link between beta amyloid peptide and tau protein. Hernández F; Gómez de Barreda E; Fuster-Matanzo A; Lucas JJ; Avila J Exp Neurol; 2010 Jun; 223(2):322-5. PubMed ID: 19782073 [TBL] [Abstract][Full Text] [Related]
39. Multitargeted drug development: Discovery and profiling of dihydroxy substituted 1-aza-9-oxafluorenes as lead compounds targeting Alzheimer disease relevant kinases. Tell V; Holzer M; Herrmann L; Mahmoud KA; Schächtele C; Totzke F; Hilgeroth A Bioorg Med Chem Lett; 2012 Nov; 22(22):6914-8. PubMed ID: 23039927 [TBL] [Abstract][Full Text] [Related]
40. Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions. Saraswati AP; Ali Hussaini SM; Krishna NH; Babu BN; Kamal A Eur J Med Chem; 2018 Jan; 144():843-858. PubMed ID: 29306837 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]